Vitality Biopharma (OTCMKTS:VBIO) Shares Cross Above 200-Day Moving Average of $0.35

Share on StockTwits

Vitality Biopharma Inc (OTCMKTS:VBIO) crossed above its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $0.35 and traded as high as $0.23. Vitality Biopharma shares last traded at $0.22, with a volume of 1,403 shares.

The company has a current ratio of 4.08, a quick ratio of 4.08 and a debt-to-equity ratio of 0.03. The stock has a fifty day simple moving average of $0.22 and a 200-day simple moving average of $0.34.

About Vitality Biopharma (OTCMKTS:VBIO)

Vitality Biopharma, Inc engages in the development of cannabinoid pharmaceuticals for the treatment of neurological and inflammatory disorders in the United States. The company's products in pipeline include VBX-100, an oral cannabinoid formulation for inflammatory bowel disease, C.difficile-associated diarrhea and colitis, and narcotic bowel syndrome; and VBX-210, a cannabinoid formulation, which is in preclinical studies for the treatment of gastrointestinal conditions.

Read More: What are municipal bonds?

Receive News & Ratings for Vitality Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vitality Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Vanguard Small-Cap Value ETF  Stock Position Lessened by Zhang Financial LLC
Vanguard Small-Cap Value ETF Stock Position Lessened by Zhang Financial LLC
Zhang Financial LLC Sells 466 Shares of iShares Select Dividend ETF
Zhang Financial LLC Sells 466 Shares of iShares Select Dividend ETF
Pettinga Financial Advisors LLC Buys 865 Shares of iShares Global Tech ETF
Pettinga Financial Advisors LLC Buys 865 Shares of iShares Global Tech ETF
Intec Pharma  Rating Increased to Buy at Zacks Investment Research
Intec Pharma Rating Increased to Buy at Zacks Investment Research
Palomar  Rating Lowered to Hold at Zacks Investment Research
Palomar Rating Lowered to Hold at Zacks Investment Research
UBS Group Initiates Coverage on Akazoo
UBS Group Initiates Coverage on Akazoo


© 2006-2019 Ticker Report